Hepatotoxicity following vincristine therapy

Nagi S.El Saghir; Katherine A. Hawkins

doi:10.1002/1097-0142(19841101)54:9<2006::AID-CNCR2820540937>3.0.CO;2-F

Hepatotoxicity following vincristine therapy

Nagi S.El Saghir, Katherine A. Hawkins

Research output: Contribution to journal › Article › peer-review

44 Scopus citations

Abstract

A patient is reported with small cell lung cancer treated with combination chemotherapy (cyclophosphamide, vincristine and etoposide [VP‐16‐213] who developed transient liver function abnormalities secondary to vincristine therapy. Serum transaminase (SGOT and SGPT) levels rose by 2 to 6 times, lactic dehydrogenase (LDH) 1.5 to 2 times, and alkaline phosphatase and gamma‐glutamyl transpeptidase (GGTP) 1.5 to 2 times normal. Enzyme abnormalities were observed by the 6th day following drug administration and returned to normal between 16 and 48 days, except for the GGTP elevations which persisted longer. Vincristine has been suspected to cause liver damage and to enhance radiation‐induced hepatic injury. The authors report this case of moderate transient transaminitis confirmed by rechallenge with vincristine.

Original language	English
Pages (from-to)	2006-2008
Number of pages	3
Journal	Cancer
Volume	54
Issue number	9
DOIs	https://doi.org/10.1002/1097-0142(19841101)54:9<2006::AID-CNCR2820540937>3.0.CO;2-F
State	Published - 1 Nov 1984
Externally published	Yes

Access to Document

10.1002/1097-0142(19841101)54:9<2006::AID-CNCR2820540937>3.0.CO;2-F

Cite this

@article{f5bc03c4d59c4653a447ba6a0e47b582,

title = "Hepatotoxicity following vincristine therapy",

abstract = "A patient is reported with small cell lung cancer treated with combination chemotherapy (cyclophosphamide, vincristine and etoposide [VP‐16‐213] who developed transient liver function abnormalities secondary to vincristine therapy. Serum transaminase (SGOT and SGPT) levels rose by 2 to 6 times, lactic dehydrogenase (LDH) 1.5 to 2 times, and alkaline phosphatase and gamma‐glutamyl transpeptidase (GGTP) 1.5 to 2 times normal. Enzyme abnormalities were observed by the 6th day following drug administration and returned to normal between 16 and 48 days, except for the GGTP elevations which persisted longer. Vincristine has been suspected to cause liver damage and to enhance radiation‐induced hepatic injury. The authors report this case of moderate transient transaminitis confirmed by rechallenge with vincristine.",

author = "Saghir, {Nagi S.El} and Hawkins, {Katherine A.}",

year = "1984",

month = nov,

day = "1",

doi = "10.1002/1097-0142(19841101)54:9<2006::AID-CNCR2820540937>3.0.CO;2-F",

language = "English",

volume = "54",

pages = "2006--2008",

journal = "Cancer",

issn = "0008-543X",

publisher = "John Wiley and Sons Inc.",

number = "9",

}

TY - JOUR

T1 - Hepatotoxicity following vincristine therapy

AU - Saghir, Nagi S.El

AU - Hawkins, Katherine A.

PY - 1984/11/1

Y1 - 1984/11/1

N2 - A patient is reported with small cell lung cancer treated with combination chemotherapy (cyclophosphamide, vincristine and etoposide [VP‐16‐213] who developed transient liver function abnormalities secondary to vincristine therapy. Serum transaminase (SGOT and SGPT) levels rose by 2 to 6 times, lactic dehydrogenase (LDH) 1.5 to 2 times, and alkaline phosphatase and gamma‐glutamyl transpeptidase (GGTP) 1.5 to 2 times normal. Enzyme abnormalities were observed by the 6th day following drug administration and returned to normal between 16 and 48 days, except for the GGTP elevations which persisted longer. Vincristine has been suspected to cause liver damage and to enhance radiation‐induced hepatic injury. The authors report this case of moderate transient transaminitis confirmed by rechallenge with vincristine.

AB - A patient is reported with small cell lung cancer treated with combination chemotherapy (cyclophosphamide, vincristine and etoposide [VP‐16‐213] who developed transient liver function abnormalities secondary to vincristine therapy. Serum transaminase (SGOT and SGPT) levels rose by 2 to 6 times, lactic dehydrogenase (LDH) 1.5 to 2 times, and alkaline phosphatase and gamma‐glutamyl transpeptidase (GGTP) 1.5 to 2 times normal. Enzyme abnormalities were observed by the 6th day following drug administration and returned to normal between 16 and 48 days, except for the GGTP elevations which persisted longer. Vincristine has been suspected to cause liver damage and to enhance radiation‐induced hepatic injury. The authors report this case of moderate transient transaminitis confirmed by rechallenge with vincristine.

UR - http://www.scopus.com/inward/record.url?scp=0021126742&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19841101)54:9<2006::AID-CNCR2820540937>3.0.CO;2-F

DO - 10.1002/1097-0142(19841101)54:9<2006::AID-CNCR2820540937>3.0.CO;2-F

M3 - Article

C2 - 6090004

AN - SCOPUS:0021126742

SN - 0008-543X

VL - 54

SP - 2006

EP - 2008

JO - Cancer

JF - Cancer

IS - 9

ER -

Hepatotoxicity following vincristine therapy

Abstract

Access to Document

Fingerprint

Cite this